(RTTNews) - On Thursday, Biofrontera Inc. (BFRI) said it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking to expand the approved use of Ameluz in combination with photodynamic therapy (PDT) for the treatment of actinic keratoses (AKs).
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.